Kenneth P Nephew

List of Publications by Year
in descending order

118 papers	9,341 citations	47006 47 h-index	39675 94 g-index
127 all docs	127 docs citations	127 times ranked	13381 citing authors

#	Article	IF	Citations
1	Aberrant epigenetic and transcriptional events associated with breast cancer risk. Clinical Epigenetics, 2022, 14, 21.	4.1	14
2	Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. Journal of Translational Medicine, 2022, 20, .	4.4	23
3	A Novel ALDH1A1 Inhibitor Blocks Platinum-Induced Senescence and Stemness in Ovarian Cancer. Cancers, 2022, 14, 3437.	3.7	6
4	Hypermethylation and global remodelling of DNA methylation is associated with acquired cisplatin resistance in testicular germ cell tumours. Epigenetics, 2021, 16, 1071-1084.	2.7	21
5	A phase 1 study of combined guadecitabine and cisplatin in platinum refractory germ cell cancer. Cancer Medicine, 2021, 10, 156-163.	2.8	23
6	How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML. Cancer Research, 2021, 81, 813-815.	0.9	0
7	Experimental competition induces immediate and lasting effects on the neurogenome in free-living female birds. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	23
8	Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival. Journal of the National Cancer Institute, 2021, 113, 1369-1378.	6.3	8
9	Targeting Ovarian Cancer Stem Cells by Dual Inhibition of HOTAIR and DNA Methylation. Molecular Cancer Therapeutics, 2021, 20, 1092-1101.	4.1	15
10	The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer. Cancer Research, 2021, 81, 3985-4000.	0.9	14
11	ZEB2 regulates endocrine therapy sensitivity and metastasis in luminal a breast cancer cells through a non-canonical mechanism. Breast Cancer Research and Treatment, 2021, 189, 25-37.	2.5	4
12	Profiling Cellâ€“Matrix Adhesion Using Digitalized Acoustic Streaming. Analytical Chemistry, 2020, 92, 2283-2290.	6.5	20
13	A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clinical Cancer Research, 2020, 26, 1009-1016.	7.0	56
14	Targeting progesterone signaling prevents metastatic ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31993-32004.	7.1	29
15	ERK5 Is Required for Tumor Growth and Maintenance Through Regulation of the Extracellular Matrix in Triple Negative Breast Cancer. Frontiers in Oncology, 2020, 10, 1164.	2.8	13
16	A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways. Anti-Cancer Drugs, 2020, 31, 759-775.	1.4	0
17	Regulation of cellular sterol homeostasis by the oxygen responsive noncoding RNA lincNORS. Nature Communications, 2020, 11, 4755.	12.8	12
18	EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells. Cancer Research, 2020, 80, 4371-4385.	0.9	37

#	Article	IF	Citations
19	Platinum-Induced Ubiquitination of Phosphorylated H2AX by RING1A Is Mediated by Replication Protein A in Ovarian Cancer. Molecular Cancer Research, 2020, 18, 1699-1710.	3.4	9
20	Turning Up the Heat on the Pancreatic Tumor Microenvironment by Epigenetic Priming. Cancer Research, 2020, 80, 4610-4611.	0.9	2
21	Epigenetic Attire in Ovarian Cancer: The Emperor's New Clothes. Cancer Research, 2020, 80, 3775-3785.	0.9	38
22	In vivoÂmodeling of metastatic human high-grade serous ovarian cancer in mice. PLoS Genetics, 2020, 16, e1008808.	3.5	27
23	Targeting Aldehyde Dehydrogenases to Eliminate Cancer Stem Cells in Gynecologic Malignancies. Cancers, 2020, 12, 961.	3.7	39
24	Glutamine Metabolism Drives Growth in Advanced Hormone Receptor Positive Breast Cancer. Frontiers in Oncology, 2019, 9, 686.	2.8	41
25	Ovarian Cancer Stem Cells: Role in Metastasis and Opportunity for Therapeutic Targeting. Cancers, 2019, 11, 934.	3.7	45
26	Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells. Cancers, 2019, 11, 43.	3.7	9
27	Interferon-Î³ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer. Npj Precision Oncology, 2019, 3, 32.	5.4	21
28	The Tumor Microenvironment of High Grade Serous Ovarian Cancer. Cancers, 2019, 11, 21.	3.7	13
29	A Phase I Clinical Trial of Guadecitabine and Carboplatin in Platinum-Resistant, Recurrent Ovarian Cancer: Clinical, Pharmacokinetic, and Pharmacodynamic Analyses. Clinical Cancer Research, 2018, 24, 2285-2293.	7.0	49
30	An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clinical Cancer Research, 2018, 24, 3163-3175.	7.0	93
31	Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. Oncogene, 2018, 37, 3589-3600.	5.9	18
32	Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. Targeted Oncology, 2018, 13, 49-60.	3.6	5
33	Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs. Cancer Research, 2018, 78, 631-644.	0.9	86
34	Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled. Cancers, 2018, 10, 295.	3.7	49
35	Changes in mRNA/protein expression and signaling pathways in in vivo passaged mouse ovarian cancer cells. PLoS ONE, 2018, 13, e0197404.	2.5	8
36	Epigenetic Targeting of Adipocytes Inhibits High-Grade Serous Ovarian Cancer Cell Migration and Invasion. Molecular Cancer Research, 2018, 16, 1226-1240.	3.4	17

#	Article	IF	Citations
37	IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight, 2018, 3, .	5.0	83
38	Therapeutic targeting using tumor specific peptides inhibits long non-coding RNA HOTAIR activity in ovarian and breast cancer. Scientific Reports, 2017, 7, 894.	3.3	110
39	MicroRNAâ€335â€5p and â€3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance. FEBS Letters, 2017, 591, 382-392.	2.8	52
40	Complete Transcriptome RNA-Seq. Methods in Molecular Biology, 2017, 1513, 141-162.	0.9	2
41	Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 2017, 8, 84579-84594.	1.8	23
42	The novel ZIP4 regulation and its role in ovarian cancer. Oncotarget, 2017, 8, 90090-90107.	1.8	27
43	Argonaute 2 Expression Correlates with a Luminal B Breast Cancer Subtype and Induces Estrogen Receptor Alpha Isoform Variation. Non-coding RNA, 2016, 2, 8.	2.6	11
44	Bisphenol A alters the self-renewal and differentiation capacity of human bone-marrow-derived mesenchymal stem cells. Endocrine Disruptors (Austin, Tex), 2016, 4, e1200344.	1.1	9
45	Long-range regulators of the lncRNAHOTAIRenhance its prognostic potential in breast cancer. Human Molecular Genetics, 2016, 25, 3269-3283.	2.9	58
46	Subtype-specific CpG island shore methylation and mutation patterns in 30 breast cancer cell lines. BMC Systems Biology, 2016, 10, 116.	3.0	12
47	BioVLAB-mCpG-SNP- EXPRESS : A system for multi-level and multi-perspective analysis and exploration of DNA methylation, sequence variation (SNPs), and gene expression from multi-omics data. Methods, 2016, 111, 64-71.	3.8	5
48	Abstract A57: Platinum induces IL-6-signaling mediated activation of ALDH1A1 and enriches the cancer stem cell population in ovarian cancer.. , 2016, , .		1
49	EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells. Oncotarget, 2016, 7, 84453-84467.	1.8	57
50	Functional characterization of a panel of high-grade serous ovarian cancer cell lines as representative experimental models of the disease. Oncotarget, 2016, 7, 32810-32820.	1.8	58
51	Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget, 2015, 6, 16638-16652.	1.8	86
52	Agonist and antagonist switch <scp>DNA</scp> motifs recognized by human androgen receptor in prostate cancer. EMBO Journal, 2015, 34, 502-516.	7.8	74
53	Stranded Whole Transcriptome RNAâ€Seq for All RNA Types. Current Protocols in Human Genetics, 2015, 84, 11.14.1-11.14.23.	3.5	7
54	Hypermethylation of the TGF-Î² target, ABCA1 is associated with poor prognosis in ovarian cancer patients. Clinical Epigenetics, 2015, 7, 1.	4.1	133

#	Article	IF	Citations
55	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
56	In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecologic Oncology, 2015, 138, 372-377.	1.4	149
57	Elevated expression of long intergenic nonâ€coding RNA HOTAIR in a basalâ€like variant of MCFâ€7 breast cancer cells. Molecular Carcinogenesis, 2015, 54, 1656-1667.	2.7	35
58	BioVLAB-MMIA-NGS: microRNAâ€“mRNA integrated analysis using high-throughput sequencing data. Bioinformatics, 2015, 31, 265-267.	4.1	38
59	Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study. PLoS ONE, 2015, 10, e0141279.	2.5	49
60	Mg2+ Effect on Argonaute and RNA Duplex by Molecular Dynamics and Bioinformatics Implications. PLoS ONE, 2014, 9, e109745.	2.5	16
61	A Mathematical Model of Bimodal Epigenetic Control of miR-193a in Ovarian Cancer Stem Cells. PLoS ONE, 2014, 9, e116050.	2.5	14
62	TGF-Î² induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics, 2014, 9, 1461-1472.	2.7	136
63	The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. Clinical Cancer Research, 2014, 20, 6504-6516.	7.0	87
64	Hypomethylation signature of tumor-initiating cells predicts poor prognosis of ovarian cancer patients. Human Molecular Genetics, 2014, 23, 1894-1906.	2.9	56
65	Epigenetic Targeting of Ovarian Cancer Stem Cells. Cancer Research, 2014, 74, 4922-4936.	0.9	136
66	Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget, 2014, 5, 3579-3589.	1.8	41
67	MiR-373 targeting of the Rab22a oncogene suppresses tumor invasion and metastasis in ovarian cancer. Oncotarget, 2014, 5, 12291-12303.	1.8	69
68	Epigenetic Targeting Therapies to Overcome Chemotherapy Resistance. Advances in Experimental Medicine and Biology, 2013, 754, 285-311.	1.6	23
69	A new method for stranded whole transcriptome RNA-seq. Methods, 2013, 63, 126-134.	3.8	59
70	3D culture adds an extra dimension to targeted epigenetic therapies. Cell Cycle, 2013, 12, 2173-2174.	2.6	1
71	Adenoviral-delivered HE4-HSV-tk sensitizes ovarian cancer cells to ganciclovir. Gene Therapy and Molecular Biology, 2013, 15, 120-130.	1.3	6
72	Role of Neurofilament Light Polypeptide in Head and Neck Cancer Chemoresistance. Molecular Cancer Research, 2012, 10, 305-315.	3.4	26

#	Article	IF	Citations
73	Altered Death Receptor Signaling Promotes Epithelial-to-Mesenchymal Transition and Acquired Chemoresistance. Scientific Reports, 2012, 2, 539.	3.3	32
74	BioVLAB-MMIA: A Cloud Environment for microRNA and mRNA Integrated Analysis (MMIA) on Amazon EC2. IEEE Transactions on Nanobioscience, 2012, 11, 266-272.	3.3	24
75	An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells. BMC Genomics, 2012, 13, 732.	2.8	22
76	Epigenetic Resensitization to Platinum in Ovarian Cancer. Cancer Research, 2012, 72, 2197-2205.	0.9	344
77	An ERα/modulator regulatory network in the breast cancer cells. , 2011, , .		1
78	BioVLAB-MMIA: A Reconfigurable Cloud Computing Environment for microRNA and mRNA Integrated Analysis. , 2011, , .		0
79	The role of chromatin, microRNAs, and tumor stem cells in ovarian cancer. Cancer Biomarkers, 2011, 8, 203-221.	1.7	15
80	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
81	Empirical bayes model comparisons for differential methylation analysis. , 2011, , .		1
82	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer. Cancer Research, 2011, 71, 6738-6748.	0.9	87
83	Cancer Stem Cells in Ovarian Cancer. , 2011, , 151-176.		0
84	Estrogen receptor-alpha-interacting cytokeratins potentiate the antiestrogenic activity of fulvestrant. Cancer Biology and Therapy, 2010, 9, 389-396.	3.4	10
85	Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecologic Oncology, 2010, 116, 195-201.	1.4	95
86	A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinumâ€resistant, epithelial ovarian cancer. Cancer, 2010, 116, 4043-4053.	4.1	139
87	Role of epigenomics in ovarian and endometrial cancers. Epigenomics, 2010, 2, 419-447.	2.1	46
88	Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics, 2010, 5, 716-729.	2.7	51
89	MicroRNA Cluster 221-222 and Estrogen Receptor Î± Interactions in Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 706-721.	6.3	301
90	MicroRNA and mRNA integrated analysis (MMIA): a web tool for examining biological functions of microRNA expression. Nucleic Acids Research, 2009, 37, W356-W362.	14.5	149

#	Article	IF	Citations
91	Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics, 2009, 25, 430-434.	4.1	129
92	Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Medical Genomics, 2009, 2, 34.	1.5	192
93	Minireview: Epigenetic Changes in Ovarian Cancer. Endocrinology, 2009, 150, 4003-4011.	2.8	136
94	Epigenetics and Ovarian Cancer. Cancer Treatment and Research, 2009, 149, 131-146.	0.5	9
95	A Rationally Designed Histone Deacetylase Inhibitor with Distinct Antitumor Activity against Ovarian Cancer. Neoplasia, 2009, 11, 552-IN9.	5.3	50
96	Methyl Group Acceptance Assay for the Determination of Global DNA Methylation Levels. Methods in Molecular Biology, 2009, 507, 35-41.	0.9	13
97	Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors. Cancer Research, 2008, 68, 4311-4320.	0.9	1,196
98	Diverse Gene Expression and DNA Methylation Profiles Correlate with Differential Adaptation of Breast Cancer Cells to the Antiestrogens Tamoxifen and Fulvestrant. Cancer Research, 2006, 66, 11954-11966.	0.9	226
99	Dominant-Negative Histone H3 Lysine 27 Mutant Derepresses Silenced Tumor Suppressor Genes and Reverses the Drug-Resistant Phenotype in Cancer Cells. Cancer Research, 2006, 66, 5582-5591.	0.9	102
100	Prognostic DNA Methylation Biomarkers in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2788-2794.	7.0	148
101	Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-?? expression in the rat uterus. Anti-Cancer Drugs, 2005, 16, 559-567.	1.4	12
102	New anti-cancer strategies: Epigenetic therapies and biomarkers. Frontiers in Bioscience - Landmark, 2005, 10, 1897.	3.0	66
103	Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Molecular Cancer Therapeutics, 2005, 4, 1505-1514.	4.1	133
104	Inhibiting Proteasomal Proteolysis Sustains Estrogen Receptor-Î± Activation. Molecular Endocrinology, 2004, 18, 2603-2615.	3.7	78
105	The epigenetics of ovarian cancer drug resistance and resensitization. American Journal of Obstetrics and Gynecology, 2004, 191, 1552-1572.	1.3	156
106	Epigenetic gene silencing in cancer initiation and progression. Cancer Letters, 2003, 190, 125-133.	7.2	167
107	The NEDD8 Pathway Is Required for Proteasome-Mediated Degradation of Human Estrogen Receptor (ER)-Î± and Essential for the Antiproliferative Activity of ICI 182,780 in ERÎ±-Positive Breast Cancer Cells. Molecular Endocrinology, 2003, 17, 356-365.	3.7	120
108	The Activating Enzyme of NEDD8 Inhibits Steroid Receptor Function. Molecular Endocrinology, 2002, 16, 315-330.	3.7	47

#	Article	IF	Citations
109	Strain differences in tamoxifen sensitivity ofSprague-Dawley and Fischer 344 rats. Anti-Cancer Drugs, 2002, 13, 939-947.	1.4	12
110	Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clinical Cancer Research, 2002, 8, 2246-52.	7.0	156
111	Effects of the Xenoestrogen Bisphenol a on Expression of Vascular Endothelial Growth Factor (VEGF) in the Rat. Experimental Biology and Medicine, 2001, 226, 477-483.	2.4	38
112	Immunohistochemical detection of estrogen receptor alpha in male rat spinal cord during development. Journal of Neuroscience Research, 2000, 61, 329-337.	2.9	20
113	Effect of Estradiol on Estrogen Receptor Expression in Rat Uterine Cell Types1. Biology of Reproduction, 2000, 62, 168-177.	2.7	91
114	Expression of Estrogen Receptor Coactivators in the Rat Uterus1. Biology of Reproduction, 2000, 63, 361-367.	2.7	40
115	Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the Rat. Proceedings of the Society for Experimental Biology and Medicine, 2000, 223, 288-294.	1.8	22
116	Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in theâ€ƒRat. Proceedings of the Society for Experimental Biology and Medicine, 2000, 223, 288-294.	1.8	3
117	Studies of dehydroepiandrosterone (DHEA) with the human estrogen receptor in yeast. Molecular and Cellular Endocrinology, 1998, 143, 133-142.	3.2	47
118	Cell-Specific Induction of c-fos Expression in the Pituitary Gland by Estrogen*. Endocrinology, 1997, 138, 2128-2135.	2.8	47